We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

150 hedge funds and large institutions have $1.14B invested in Keryx Biopharmaceuticals Inc in 2014 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 52 increasing their positions, 44 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

173% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 15

73% more capital invested

Capital invested by funds: $660M → $1.14B (+$484M)

21% more funds holding

Funds holding: 124150 (+26)

18% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 44

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

12% more call options, than puts

Call options by funds: $32.6M | Put options by funds: $29.1M

Holders
150
Holders Change
+26
Holders Change %
+20.97%
% of All Funds
4.33%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.2%
New
41
Increased
52
Reduced
44
Closed
15
Calls
$32.6M
Puts
$29.1M
Net Calls
+$3.44M
Net Calls Change
-$4.51M
Name Holding Trade Value Shares
Change
Change in
Stake
NC
26
Northpointe Capital
Michigan
$15M -$6.21M -411,836 -32%
QF
27
QVT Financial
New York
$14.2M -$284K -18,800 -2%
O
28
OppenheimerFunds
New York
$14M +$806K +53,427 +7%
JHIU
29
Janus Henderson Investors US
Colorado
$11.1M +$9.87M +654,234 New
ICRM
30
Insight Capital Research & Management
California
$10M -$4.11M -272,168 -32%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$9.12M +$606K +40,192 +8%
Geode Capital Management
32
Geode Capital Management
Massachusetts
$8.4M +$1.52M +100,735 +26%
Lord, Abbett & Co
33
Lord, Abbett & Co
New Jersey
$7.35M -$6.2M -411,267 -49%
MAA
34
Managed Account Advisors
New Jersey
$7.02M +$2.78M +184,365 +81%
TCIM
35
TIAA CREF Investment Management
New York
$5.79M +$200K +13,245 +4%
CCM
36
Cupps Capital Management
Illinois
$5.44M +$4.82M +319,275 New
NFA
37
Nationwide Fund Advisors
Ohio
$5.12M +$1.29M +85,642 +40%
GC
38
Guggenheim Capital
Illinois
$5.06M +$1.2M +79,786 +37%
AAMU
39
Amundi Asset Management US
Massachusetts
$4.84M +$4.29M +284,299 New
PA
40
Perceptive Advisors
New York
$4.69M +$4.15M +275,000 New
Principal Financial Group
41
Principal Financial Group
Iowa
$4.57M -$5.33K -353 -0.1%
RPAM
42
Rhenman & Partners Asset Management
Sweden
$4.52M -$2.03M -134,675 -34%
ARTA
43
A.R.T. Advisors
New York
$4.42M +$2.59M +171,488 +195%
BIM
44
BlackRock Investment Management
Delaware
$4.19M +$325K +21,520 +10%
WC
45
Wexford Capital
Florida
$4.15M -$2.73M -181,145 -43%
EI
46
EAM Investors
California
$3.93M -$183K -12,131 -5%
Charles Schwab
47
Charles Schwab
California
$3.93M +$625K +41,404 +22%
Citadel Advisors
48
Citadel Advisors
Florida
$3.51M +$562K +37,224 +22%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$3.44M +$298K +19,750 +10%
KCM
50
Knoll Capital Management
Florida
$3.41M

KERX Hedge Fund Activity: Q1 2014 in Review

150 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q1 2014, worth a combined $1.14B — up 73% from $660M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new KERX positions and 15 closed out — a net gain of 26 holders — while 52 added to existing stakes and 44 trimmed.

The largest buyer was Baupost Group, opening a new position worth an estimated $95.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $22M sold.

  • 150 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q1 2014, up from 124 in Q4 2013.
  • Funds reported $1.14B of Keryx Biopharmaceuticals Inc stock for Q1 2014, up 73% quarter-over-quarter.
  • 41 funds opened new Keryx Biopharmaceuticals Inc positions in Q1 2014 and 15 closed out, a net change of +26 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q1 2014 was Baupost Group, an estimated $95.2M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q1 2014 was Cormorant Asset Management, an estimated $22M sold.

Based on aggregated 13F filings for Q1 2014.